Autres langues XOMA Corporation

Actions

XOMA

US98419J2069

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
25,41 ^USD	+0,20%		-0,27%	+37,35%

03/04	XOMA Corporation (NasdaqGM:XOMA) a conclu l'acquisition de Kinnate Biopharma Inc. (NasdaqGS:KNTE).	CI
08/03	XOMA Corporation annonce ses résultats pour l'année complète terminée le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	25/04
XOMA : Acquisition/Asset Disposal - Form 8-K	03/04
XOMA Corporation Announces Closing of Tender Offer	03/04
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	03/04
XOMA Declares Quarterly Preferred Stock Dividends	21/03
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	19/03
Xoma: Q4 Earnings Snapshot	08/03
XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	08/03
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value	08/03
XOMA to Present at Upcoming Investor Conferences in March	28/02
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right	19/02
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA	16/02
Sector Update: Health Care Stocks Advance Friday Afternoon	16/02
XOMA Agrees to Acquire Kinnate Biopharma	16/02
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right	16/02
XOMA Corporation entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. for approximately $120 million.	16/02
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition	19/01
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million	18/01
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition	18/01
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million.	18/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues XOMA Corporation

Actions

XOMA

US98419J2069

Autres langues

Filtres